Biological
Rocakinogene sifuplasmid clinical trials
Also written INO-9012 and INO-9112.
- studies test it
- 11
- open now
- 1
- in phase 3
- 0
- first study started
- 2014
Keep track of what changes. Save the rocakinogene sifuplasmid studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Combined with it in one product
Studies by the year they started
11 studies that test it; most in 2018 (3)
| Year | Studies |
|---|---|
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 3 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 10
- Phase 2
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 3
Inovio Pharmaceuticals (6) · Geneos Therapeutics (2) · University of Pennsylvania (1) · National Cancer Institute (NCI) (1) · Steven Deeks (1)
Often tested with
Tested in the same studies.
WT1/PSMA/hTERT-encoding Plasmid DNA INO-5401 (2) · Cemiplimab (1) · Pembrolizumab (1) · Electroporation-Mediated Plasmid DNA Vaccine Therapy (1) · HCV DNA Vaccine INO-8000 (1) · Atezolizumab (1) · INO-6145 (1) · INO-1800 (1)
Studies
Open first, then newest update. How each study uses rocakinogene sifuplasmid is read from its arms, and is right about nine times in ten.
Testing it · 11
- Personalized Neoantigen Vaccine Plus IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCCRecruitingPhase 2Geneos TherapeuticsNCT07722741Written as INO-9012
- INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)Active, not recruitingPhase 1/2Inovio PharmaceuticalsNCT03491683Written as INO-9012
- INO 5401 Vaccination in BRCA1/2 Mutation CarriersActive, not recruitingPhase 1University of PennsylvaniaNCT04367675Written as INO-9012
- GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCCActive, not recruitingPhase 1/2Geneos TherapeuticsNCT04251117Written as INO-9012
- DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus InfectionActive, not recruitingPhase 1National Cancer Institute (NCI)NCT02772003Written as Rocakinogene Sifuplasmid
- INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial CarcinomaCompletedPhase 1/2Inovio PharmaceuticalsNCT03502785Written as INO-9012
- Therapeutic Vaccination in Treated HIV DiseaseCompletedPhase 1/2Steven DeeksNCT03606213Written as INO-9012
- Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy VolunteersWithdrawnPhase 1Inovio PharmaceuticalsNCT05430958Written as INO-9112
- Phase I Study of INO-1800 With or Without INO-9112 + EP in Chronic Hepatitis B SubjectsCompletedPhase 1Inovio PharmaceuticalsNCT02431312Written as INO-9112
- hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of RelapseCompletedPhase 1Inovio PharmaceuticalsNCT02960594Written as INO-9012
- Immunotherapy in Subjects With HPV-6 Associated Aerodigestive Precancerous Lesions and MalignanciesCompletedPhase 1Inovio PharmaceuticalsNCT02241369Written as INO-3106, INO-9012
Given in every arm · 1 — rocakinogene sifuplasmid is usual care beside what is tested
Codes
What other systems call rocakinogene sifuplasmid · ClinicalTrials.gg INT001873
- MeSH (NLM) C000722693rocakinogene sifuplasmidConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 91JHE0ANN8ROCAKINOGENE SIFUPLASMIDConfirmed FDA, NLM
- NCI Thesaurus C116709Rocakinogene SifuplasmidOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000722693 | rocakinogene sifuplasmid | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 91JHE0ANN8 | ROCAKINOGENE SIFUPLASMID | Confirmed FDA, NLM |
| NCI Thesaurus | C116709 | Rocakinogene Sifuplasmid | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.